Replies to post #165949 on Biotech Values

[DewDiligence]

SDRX logs a pretty good quarter, but market is not impressed:

http://finance.yahoo.com/news/surmodics-reports-fourth-quarter-full-211500485.html

I haven’t followed this company closely in a while, but I may take a look. The operating-margin and RoE numbers are respectable. SRDX has new management and is a very different company from the days when it relied on JNJ stent royalties for much of its revenue (#msg-91652915).